Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and ...(598 in patients with chronic hepatitis ....)

C virus (HCV) infection in the third quarter of 2008.

-- Initiation of Phase I Clinical Trial for ANA773. In late February,

Anadys announced that patient dosing had commenced in a Phase I study

of ANA773, the Company's oral TLR7 agonist prodrug, in patients with

advanced solid tumors. This first-in-human trial is a safety and

tolerability study designed to identify pharmacologically active doses

and preliminary antitumor activity as well as to select the dose and

schedule for Phase II trials.

Recent Scientific Presentations

-- ANA598. Earlier this month, Anadys presented a late-breaker oral

presentation at the 21st International Conference on Antiviral Research

(ICAR) in Montreal providing updated preclinical data on ANA598. The

data presented at ICAR included preclinical attributes of the product

candidate that support the potential for beneficial combination of

ANA598 with several other anti-HCV agents. Specifically, ANA598 was

reported to be highly synergistic with interferon-alpha and

non-antagonistic with ribavirin in cell-based assays. ANA598 was also

shown to retain full activity against a number of replicon mutations

known to confer resistance to other anti-HCV agents currently in

clinical development, including protease inhibitors and nucleoside

polymerase inhibitors.

-- ANA773. Anadys presented data on ANA773 earlier this month in two

poster sessions at the Annual Meeting of the American Association for

Cancer Research (AACR) in San Diego. One of the posters, based on work

done with the Moores Cancer Center at the University of California San

Diego, reported the pro-apoptotic effect of the active metabolite of

ANA773 on human chronic lymphocytic leukemia (CLL) cells ex vivo, and'/>"/>